Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+6.6%
3 months
+18.0%
6 months
+15.3%
1 year
+41.9%
Year to date
+38.4%
52-week range
$52.19 – $78.03
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$126.62B
P/E
15.6
P/B
-56.9
P/S
5.4
Revenue
$23.52B
Net income
$8.12B
Diluted EPS
4.85
Gross margin
63.30%
Net margin
34.50%
Return on equity
-279.70%
Total debt
$24.06B
Cash
$2.7B
Free cash flow
$9.07B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$6.13B
$2.52B
64.30%
41.10%
$3B
Jun 30, 2026
$6.11B
$2.3B
62.50%
37.60%
$662M
Mar 31, 2026
$5.43B
$2.18B
64.60%
40.20%
$2.23B
Dec 31, 2025
$5.85B
$1.12B
62.10%
19.10%
$3.18B
Sep 30, 2025
$6.07B
$2.38B
62.80%
39.10%
$3.04B
Jun 30, 2025
$6.1B
$2.38B
63.10%
39.00%
$173M
Mar 31, 2025
$5.26B
$1.08B
61.80%
20.50%
$2.68B
Dec 31, 2024
$5.97B
$3.04B
60.30%
50.90%
$3.29B
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
This article examines how an $800,000 portfolio split equally among Altria, Edison International, International Paper, and AT&T could generate over $44,000 in annual passive income. It details the yield and risks associated with each company, highlighting International Paper's weak dividend coverage and Edison International's wildfire liabilities, while noting Altria's high yield and AT&T's commitment to its dividend through 2028. The author emphasizes that steady cash flow from staggered quarterly payments is crucial for retirees.
Thermo Fisher Scientific (TMO) has approved a new $5 billion share repurchase authorization. This new program will replace the previous buyback authorization, which had approximately $1 billion remaining. The announcement indicates a continued commitment to returning capital to shareholders.
Lisa P. Britt, an officer at Thermo Fisher Scientific Inc. (TMO), has proposed selling 2,831 common shares with an aggregate market value of nearly $2 million. The sale is scheduled for approximately October 28, 2026, through Fidelity Brokerage Services LLC on the NYSE. Britt had previously sold a significant number of shares in August 2026, totaling over $10 million.